Lyka Labs
- Market cap
- ₹ 302 Cr.
- P/E
- 127x
- P/B
- 3.19x
- 52-week range
- 44.1 – 98.25
- ROE
- −10%
- ROCE
- −6%
- Dividend yield
- 0%
- Debt / equity
- 0.53
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Lyka Labs Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of quality finished dosages. The Company manufactures pharmaceutical products such as Dry Powder, Liquid, Lyophilized Injections and External Preparations for several International Markets and the Domestic Market. The Company’s R&D is engaged in the development of new formulations and has developed several products in the categories, such as Injectables: Lyophilized Injection, Liquid Injections & Dry Powder Injections, and Topical Preparation: Ointment /Creams and Lotions. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, antifungal, anti-malarial, antibacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Lyka Labs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)127 against a typical 34.3: pricier than most peers (1st = cheapest).199th of 220
- Sales growth+28.1% against a typical +15.6% from a year earlier.60th of 197
- Profit growth+107.1% against a typical +18.9% from a year earlier.31st of 160
- Share price, 3 months+29.3% against a typical −0.5%.22nd of 200
- Size₹ 302 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).108th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by India Ratings- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND BBB+; IND A2 | Stable | 30 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 30 Apr 2026 | Reaffirmed | IND BBB+ | — | India Ratings | ₹ 33.28 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 10 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 25 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 31 Mar 2026 | Other business matters | To consider other business matters |
| 29 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 29 Sep 2025 | Other business matters | To consider other business matters for redemption of Preference Shares and Appointment of Company Secretary and Compliance Officer |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 33 | 28 | 30 | 41 | 34 | 33 | 33 | 37 | 31 | 28 | 42 |
| Expenses | 24 | 26 | 26 | 26 | 36 | 29 | 29 | 29 | 39 | 29 | 34 | 38 |
| Operating Profit | 4 | 7 | 2 | 4 | 5 | 5 | 4 | 4 | −3 | 2 | −6 | 5 |
| OPM % | 14.9% | 21.1% | 7.3% | 12.3% | 12% | 15.4% | 12.2% | 11.1% | −6.9% | 5.4% | −23% | 10.8% |
| Other Income | −0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | −1 | 3 | −2 | 2 | 3 | 4 | 3 | 1 | −4 | −0 | −9 | 2 |
| Tax % | −22.8% | 38.6% | 28.2% | 30.7% | 28.4% | 24.3% | 32.9% | 26.7% | −26.7% | −6.3% | −6.1% | −5.1% |
| Net Profit | −0 | 2 | −2 | 1 | 2 | 3 | 2 | 1 | −3 | −0 | −8 | 2 |
| EPS in Rs | −0.15 | 0.54 | −0.63 | 0.4 | 0.59 | 0.76 | 0.5 | 0.26 | −0.94 | 0 | −2.13 | 0.57 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 0%
- 5 Years
- 8%
- 3 Years
- 11%
- TTM
- −3%
- 10 Years
- —
- 5 Years
- 1%
- 3 Years
- −32%
- TTM
- −219%
- 10 Years
- 1%
- 5 Years
- 0%
- 3 Years
- −14%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Lyka Labs | ₹ 77.42 | ₹ 302 Cr. | 127x | 3.2x | −10% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Kunal Narendra Gandhi
- Chief Executive Officer, Managing Director, Executive Director
- Yogesh B. Shah
- Chief Financial Officer, Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.